SEC Form 4 · accession 0001562180-18-004313
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carrie Smith Cox
Director
Period of report
Oct 25, 2018
Accepted (ET)
Oct 29, 2018 · 6:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $14.55 | Oct 25, 2018 | A | 25,000 | A | — | Oct 25, 2028 | Common Stock | 25,000 | 25,000 | D |
| Restricted Stock UnitsF2 | $0.00 | Oct 25, 2018 | A | 5,000 | A | — | — | Common Stock | 5,000 | 5,000 | D |
Explanation of responses
- F1The options vest in full on October 25, 2019, subject to continued service on Array BioPharma Inc.'s ("Array") board of directors.
- F2Restricted Stock Units ("RSUs") awarded to the reporting person for no additional cash consideration and each represents a contingent right to receive one share of common stock. The RSUs vest in full and will be settled in common stock on October 25, 2019, subject to continued service on Array's board of directors.